Journal article
Safety of Degludec versus Glargine in Type 2 Diabetes
The New England journal of medicine, Vol.377(20), pp.1994-1996
11/16/2017
DOI: 10.1056/NEJMc1712575
PMID: 29141162
Abstract
To the Editor:
In reporting the results of the Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE), Marso et al. (Aug. 24 issue)
1
report a lower risk of hypoglycemia among patients who received insulin degludec than among those who received insulin glargine, without significant differences in basal insulin doses, monitored plasma glucose or glycated hemoglobin levels, or concomitant medications. Although the use of prandial insulin was similar in the two groups, no information was provided on the actual doses administered. The distribution of risk factors . . .
Details
- Title: Subtitle
- Safety of Degludec versus Glargine in Type 2 Diabetes
- Creators
- Amie A Ogunsakin - University of Tennessee Health Science CenterNidhi Jain - University of Tennessee Health Science CenterSamuel Dagogo-Jack - University of Tennessee Health Science CenterJohn A Tayek - Harbor–University of California, Los Angeles (UCLA) Medical Center, Torrance, CAPaul N.N Danese - FDAble, Glastonbury, CTMichael S Smith - Harbor–UCLA Medical CenterRiccardo Perfetti - Sanofi, Bridgewater, NJSteven P Marso - Research Medical CenterJohn B Buse - University of North Carolina at Chapel Hill
- Resource Type
- Journal article
- Publication Details
- The New England journal of medicine, Vol.377(20), pp.1994-1996
- Publisher
- Massachusetts Medical Society
- DOI
- 10.1056/NEJMc1712575
- PMID
- 29141162
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Language
- English
- Date published
- 11/16/2017
- Academic Unit
- Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984359807802771
Metrics
8 Record Views